Cardinal Health, IncNYSE: CAH
Health Care · Health Care Distributors
$222.34
-1.74%
Vol: 2.1M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16Cardinal Health back in focus as fresh Wall Street research reshapes its price-target debate with mixed analyst calls.Mixed▶
A mid-June 2026 wave of Street research has put Cardinal Health back on investors' radar, with firms split between trimming and raising targets following the company's strong fiscal Q3 2026 results (adjusted EPS of $3.17 and raised full-year guidance to $10.70-$10.80, despite a $184 million goodwill impairment). The reframed narrative reflects a divide: some analysts see further upside if execution holds, while others are cautious about valuation after the stock's ~39% one-year run. The consensus 12-month target sits around $245, with a high of $275 and a low of $215, and the stock carries a Strong Buy consensus (14 buys, 0 sells). The bull case rests on theranostics expansion (Actinium-225 capacity) and pharma distribution strength; the bear case centers on margin pressure, the goodwill write-down, and how much investors should pay after a large rally. The mixed tone suggests the easy gains may be behind the stock.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Cardinal Health raises FY26 guidance and dividend, and partners with Shine Technologies on domestic radiopharmaceutical productionPositive▶
Cardinal Health's Board approved a quarterly dividend increase to $0.5158 per share on May 5. On the same day, the company announced a partnership with Shine Technologies to scale domestic production of radiopharmaceuticals. Cardinal raised FY26 adjusted EPS guidance to $10.70-$10.80 (from $10.15-$10.35) and lifted free cash flow view to $3.3B-$3.7B (from $3.0B-$3.5B), while lowering its FY26 tax rate to 19% from 21-23%. The company released its 2026 Advanced Therapies Report focused on community-based care delivery. Following Q3 fiscal results on April 30 that delivered 11% revenue and 35% adjusted EPS growth (but slight revenue miss), JPMorgan trimmed its PT to $215 from $243. Analyst consensus across 17 analysts remains Strong Buy with an average PT of $245.27.
May 20Cardinal Health expanded domestic radiopharmaceutical production with Shine Technologies on May 5 and raised its quarterly dividend to $0.5158/share, while JPMorgan trimmed its price target to $215 from $243.Mixed▶
Cardinal Health announced an Ac-225 radiopharmaceutical production capacity expansion with Shine Technologies on May 5 to meet growing demand for novel cancer therapies. The board approved a quarterly dividend hike to $0.5158/share the same day. However, JPMorgan analyst Lisa Gill cut her price target to $215 from $243 (Neutral) following a Q3 print where revenue came in slightly below FactSet consensus and shares fell 7% intraday on April 30. The company has projected 30% adjusted EPS growth for FY2026 despite a 9.4% YTD decline. Risk: revenue softness despite EPS beats suggests margin-driven growth that may face limits as analyst targets reset lower.
May 19Cardinal Health shares rose 4.3% as investors digested dividend increase and Shine Technologies radiopharmaceutical partnership.Positive▶
Cardinal Health raised its quarterly dividend to $0.5158 per share on May 5, 2026. The same day, Cardinal and Shine Technologies announced plans to ramp domestic production of radiopharmaceuticals. Shares rose 4.3% to $194.38 on May 14, 2026. Q3 FY26 had delivered 11% revenue and 35% adjusted EPS growth. Morgan Stanley issued a Buy on May 5; JPMorgan lowered PT to $215 from $243 on May 4. Mean PT $245.27 implies 22.78% upside. Bear case: Pharma segment slightly missed FactSet consensus, and regulatory/pricing pressures persist.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Cardinal Health presented at BofA Healthcare Conference May 13; JPMorgan set $215 PT on May 4 after FY26 EPS guide raised to $10.70-$10.80.Positive▶
Cardinal Health presented at the Bank of America Global Healthcare Conference on May 13, with CFO Aaron Alt highlighting raised full-year FY2026 non-GAAP EPS guidance to $10.70-$10.80. Q3 FY2026 results showed revenue up 11% to $61B and gross profit up 18% to $2.5B, with adjusted EPS of $3.17 beating estimates by $0.38. JPMorgan provided a $215 price target on May 4 with a Neutral rating, while TD Cowen raised its target to $255 from $251 on May 1 with a Buy. Baird lowered its target to $248 from $257 on May 1 maintaining Outperform. The company also released its 2026 Advanced Therapies Report on community-based care. Risk: pharma distribution margin pressure and Optum/Express Scripts dynamics.
May 14Cardinal Health presents at BofA Healthcare Conference and partners with Shine on US radiopharmaceutical production amid mixed analyst viewsMixed▶
On May 13, 2026, Cardinal Health presented at the Bank of America Global Healthcare Conference with CFO Aaron Alt and VP of IR Dave Frost. On May 5, Cardinal Health and Shine Technologies announced a partnership to scale up domestic production of radiopharmaceuticals, expanding Cardinal's specialty distribution capabilities. The company also released its 2026 Advanced Therapies Report on shifting community-based care delivery. Analyst views are mixed: JPMorgan lowered its price target to $215 from $243 on May 4, while Morgan Stanley issued a Buy rating on May 5. Shares trade near $185.92 (market cap ~$43.66B), down 9.4% over six months despite $250.7B in trailing revenue. Analyst targets range from $215 to $275.
May 13Cardinal Health board approves quarterly dividend increase to $0.5158 per share on May 5 alongside expanded radiopharmaceutical production with Shine Technologies.Positive▶
On May 5, 2026, Cardinal Health's Board of Directors approved an increase to its quarterly dividend to $0.5158 per share. The same day, Cardinal Health and Shine Technologies announced expanded domestic production of actinium-225, a radionuclide used for cancer treatment, at a facility in Indianapolis. Morgan Stanley issued a Buy rating on May 5, while JPMorgan had lowered its price target to $215 from $243 on May 4. The company also released its 2026 Advanced Therapies Report focusing on the shift toward community-based care. Shares were trading around $182.84 with analysts seeing roughly 15% upside.
May 12Cardinal Health shares sold by Swiss Life as JP Morgan sets $215 PT following Q3 FY26 EPS beat and raised guidancePositive▶
Cardinal Health reported Q3 FY26 EPS of $3.17 (vs $2.79 consensus) on April 30, beating profit but missing revenue ($60.94B vs $62.10B est.). Management raised FY26 adjusted EPS guidance to $10.70-$10.80 (from $10.15-$10.35). On May 1, TD Cowen raised PT to $255 (Buy); Citigroup trimmed PT to $245 (Buy). JP Morgan set a $215 PT on May 4. Swiss Life Asset Management disclosed reducing its CAH stake by 9.6%. Board increased quarterly dividend to $0.5158 per share, payable July 15.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $750.08 | -3.81% | -0.5% | 14.9x | 0.32 | $87.9B |
| CORCENCORA | $271.88 | -1.88% | +2.7% | 13.7x | 0.59 | $52.9B |
| CAHCARDINAL | $222.34 | -1.74% | +11.3% | 18.5x | 0.53 | $51.9B |
| HSICHENRY | $79.92 | -0.06% | +9.1% | 13.5x | 0.82 | $9.1B |
| LLYELI | $1,099.89 | -1.09% | +7.8% | 24.7x | 0.52 | $979.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.